



EUROPEAN Society for Hyperthermic
Oncology – 37th Annual Meeting

4–6 October 2026
Erlangen, Germany

PROGRAMME PLANNER



ABSTRACTS



TABLE OF CONTENTS

General information	3
Programme overview	4
Scientific programme	
Sunday, 4 October	6
Monday, 5 October	9
Tuesday, 6 October	14
Floor plan/Exhibition	18
Sponsors	19
Social programme	20

Design/layout

Layout	Congressmanagement & Marketing GmbH
Print	Onlineprinters GmbH
	Dr.-Mack-Straße 83 90762 Fürth, Germany
Circulation	250
Editorial deadline	23 September 2026

Venue

Hörsäle Medizin
Friedrich-Alexander-Universität Erlangen-Nürnberg
Ulmenweg 18 | 91054 Erlangen, Germany

Date

4–6 October 2026

Scientific organizer

European Society for Hyperthermic Oncology (ESHO)
www.esho.info



Conference presidents

Prof. Dr. Udo Gaipl
Head of Translational Radiobiology
Department of Radiation Oncology, Universitätsklinikum Erlangen

Prof. Dr. Benjamin Frey
Translational Radiobiology
Department of Radiation Oncology, Universitätsklinikum Erlangen

Prof. Dr. Stefanie Corradini
Director of the Department of Radiation Oncology
Universitätsklinikum Erlangen

Scientific committee

Hans Crezee, The Netherlands
Pirus Ghadjar, Germany
Lars Lindner, Germany
Emanuel Stutz, Switzerland
Jorge Contreras, Spain
Valeria Milani, Switzerland
Oliver Riesterer, Switzerland
Gerard C. van Rhoon, The Netherlands
Hana Trefna, Sweden
Rüdiger Wessalowski, Germany
Anton Rink, The Netherlands

Sergio Curto, The Netherlands
Adela Ademaj, Switzerland
Ifigenia Vasiliadou, United Kingdom
Anthony Kong, United Kingdom
Sara Ramela, Italy
Arlene Oei, The Netherlands
Tessa Coenraad, The Netherlands
Katharina Brück, The Netherlands
Christoph Bert, Germany
Oliver Ott, Germany

Conference organization

Conventus Congressmanagement & Marketing GmbH
Carl-Pulfrich-Straße 1 | 07745 Jena, Germany
Sabrina Heinrich
Phone +49 3641 3116-351
esho@conventus.de | www.conventus.de

conventus
CONGRESSMANAGEMENT

PROGRAMME OVERVIEW

Sunday, 4 October

Workshop room 1	Workshop room 2
-----------------	-----------------

13:00–14:00	13:00–14:00
Educational II Challenges of Capacitive HT p. 6	Educational I Immune Effects of HT p. 6
14:00–15:00	14:00–15:00
Focused Workshop Re-irradiation and Hyperthermia in Breast Cancer p. 7	Educational III HT in Spain - reimbursement issues p. 7
15:00–16:00	
Trial Meeting I “Atzelsberger Circle” p. 7	
16:00–17:00	
yESHO Meeting p. 8	
17:00–18:00	
ESHO Board Meeting p. 8	
18:00–22:00	
Get together p. 20	

Workshop
Assemblies
Social programme
Opening, awards, closing
Keynote lecture
Scientific session
Special session
Poster session
Industrial symposium

PROGRAMME OVERVIEW

Monday, 5 October

Lecture hall 1	
08:15–08:30	
Welcome notes	p. 9
08:30–09:00	
Keynote 1	p. 9
09:00–10:30	
Session 1 Quality assurance for treatment delivery	p. 9

11:00–11:30	
Keynote 2	p. 10
11:30–13:00	
Session 2 Clinical implementation multimodal therapies	p. 10

13:45–14:15	
Keynote 3	p. 11
14:15–15:30	
Session 3 Innovative multimodal delivery techniques	p. 11
15:30–16:00	
ESHO Award 2026	p. 12

16:30–18:00	
Session 4 Technical, clinical, innovative, educational, legal and economic aspects	p. 12
18:00–18:30	
Introducing ESTRO HT FG	p. 13

19:00–22:00	
Social evening	p. 20

Tuesday, 6 October

Lecture hall 1	
08:30–09:00	
Introducing ESHO Capacitive HT Working Group	p. 14
09:00–09:30	
Keynote 4	p. 14
09:30–10:15	
Challenges of acceptance of HT	p. 14

10:45–12:00	
Poster session <i>Seminar rooms 1&2</i>	p. 14

12:00–13:30	
Session 5 Biology, translation and model systems	p. 14

13:30–14:30	
Industrial Symposium	p. 15

14:30–15:00	
Keynote 5	p. 16

15:00–16:30	
Session 6 Clinical trials	p. 16

17:00–17:45	
Round Table: “Where we go”	p. 17
17:45–18:00	
Farewell	p. 17

- 13:00–14:00 **Challenges of Capacitive HT**
 Room Workshop room 1
 T. Ohguri (Kitakyushu/JP)
- 13:00–13:20 **OP-003** – Capacitive Hyperthermia: From Evidence to Clinical Implementation
 P. Ghadjar (Berlin/DE)
- 13:20–13:30 **OP-004** – Impact of the variation in device parameters of commercial capacitive hyperthermia systems on heating effectiveness: the need for dedicated quality assurance
P. Kok (Amsterdam/NL), T. Ohguri (Kitakyushu/JP), F. Navarro (Málaga/ES)
 U. S. Gaipl (Erlangen/DE), C. A. Minnaar (Johannesburg/DE)
 J. Contreras (Málaga/ES), P. Ghadjar (Berlin/DE), J. Crezee (Amsterdam/NL)
 K. Kuroda (Hiratsuka-shi, Kanagawa, Chiba/JP)
- 13:30–13:40 **OP-005** – Waveform-Optimized Magnetic Hyperthermia Produces Glioblastoma Regression in Mice Using Trapezoidal Pulsed Fields
J.-J. Serrano-Olmedo, M. Ramos Gómez (Pozuelo de Alarcon, Madrid/ES)
 M. R. Rodríguez García, S. Martínez Moreno (Pozuelo de Alarcon/ES)
- 13:40–13:50 **OP-006** – A Configurable RF Exposure Platform for Reproducible *In Vitro* Investigation of Thermal and Non-Thermal Electromagnetic Field Effects
 A. Dieper, M. V. Scharr, L. Hammerich, D. Zips, J. Bauer (Berlin/DE)
 R. M. Fuchsli (Winterthur/CH), P. Ghadjar (Berlin/DE)
M. S. Weyland (Winterthur/CH)
- 13:50–14:00 **OP-007** – International Survey on Clinical Practice Patterns of Capacitive Hyperthermia: An Initiative of the ESHO Capacitive Hyperthermia Working Group
T. Ohguri (Kitakyushu/JP), J. Crezee, P. Kok (Amsterdam/NL)
 C. A. Minnaar, (Johannesburg/ZA), K. Kuroda (Tokai/JP), U. S. Gaipl (Erlangen/DE)
 F. Navarro, J. Contreras (Málaga/ES), P. Ghadjar (Berlin/DE)
- 13:00–14:00 **Immune Effects of HT**
 Room Workshop room 2
 Chair J. Crezee (Amsterdam/NL)
- 13:00–13:30 **OP-001** – Hyperthermia, Immunity and the Biology of Heat: From Fever-Inspired Therapy to Modern Technology
 A. L. Oei (Amsterdam/NL)

- 13:30–14:00 **OP-002** – Versatile immune modulation by hyperthermia in combination with radiotherapy
U. S. Gaipl (Erlangen/DE)
- 14:00–15:00 **Re-irradiation and Hyperthermia in Breast Cancer**
Room Workshop room 1
Chair A. Kong (London/GB)
- 14:00–14:15 **OP-010** – Adjuvant Reirradiation and Hyperthermia in Recurrent Breast Cancer: Current Practice and Future Perspectives
O. Riesterer (Aarau/CH)
- 14:15–14:30 **OP-011** – Locoregional Breast Cancer Recurrence: From Classification to the Management of Inoperable Disease
M. Nötter (Bern/CH)
- 14:30–14:45 **OP-012** – External Beam Reirradiation in Breast Cancer Recurrence: Current Evidence and ESTRO Activities
S. Corradini (Erlangen/DE)
- 14:45–15:00 **OP-013** – General Discussion
- 14:00–15:00 **HT in Spain - reimbursement issues**
Room Workshop room 2
Chair G. C. van Rhoon (Rotterdam/NL)
- 14:00–14:45 **OP-008** – Current status of oncological hyperthermia in Spain: legal and reimbursement issues
J. Contreras (Málaga/ES)
- 14:45–15:00 **OP-009** – General Discussion
- 15:00–16:00 **“Atzelsberger Circle”**
Room Workshop room 1
Chair O. J. Ott, S. Corradini (Erlangen/DE)
- 15:00–15:30 **OP-015** – Past and Future
R. Fietkau (Erlangen/DE)

- 15:30–15:40 **OP-016** – Durable Local Control with Definitive Radiotherapy and Regional Hyperthermia in Unresectable Soft Tissue Sarcoma: A Retrospective Cohort Analysis
R. L. Zuber, A. Burkhard-Meier, D. Di Gioia, V. Jurinovic, M. Hoberger
M. Völkl, S. Güler, M. Albertsmeier, A. Klein, H. R. Dürr, S. Mansoorian
N.-S. Schmidt-Hegemann, P. Rogowski, T. Knösel, W. G. Kunz (Munich/DE)
E. Stutz (Bern/DE), M. von Bergwelt-Baildon, C. Belka, L. H. Lindner
L. M. Berclaz (Munich/DE)
- 15:40–15:50 **OP-017** – Clinical Experience in Treating Low-Seated Hyperthermia Target Volumes Near the Vulva with Hyperthermia and Radiotherapy
I. Popescu, A. Rink, B. Kodde, W. Henrike, M. Franckena, P. V. Granton
S. Curto (Rotterdam/NL)
- 15:50–16:00 **OP-018** – Timing Matters: Regional Thermochemotherapy During Early Local Failure in High-Risk Pediatric Rhabdomyosarcoma
R. Wessalowski, F. Babor, K. Harder, O. Mils, C. Staude, C. Matuschek
F. Ziayee, C. Vokuhl, L. H. Lindner, R. Issels, A. Borkhardt (Duesseldorf/DE)
- 16:00–17:00 **yESHO Meeting**
Room Workshop room 1
- 17:00–18:00 **ESHO Board Meeting**
Room Workshop room 1
- 18:00–22:00 **Get together** (see page 20)

- 08:15–08:30 **Welcome notes**
 Room Lecture hall 1
 Prof. Dr.-Ing. Joachim Hornegger, President, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- 08:30–09:00 **Keynote 1**
 Room Lecture hall 1
 Chair S. Curto (Rotterdam/NL)
- 08:30–09:00 **KL-001** – Challenges of power deposition and Heat transfer in tissue: the requirements for effective hyperthermia in combination with innovative cancer therapies
 J. Crezee (Amsterdam/NL)
- 09:00–10:30 **Quality assurance for treatment delivery**
 Room Lecture hall 1
 Chair H. Dobsicek Trefna (Gothenburg/SE), S. Curto (Rotterdam/NL)
- 09:00–09:15 **OP-019** – Comparison of TFI and PDF for Susceptibility Correction in MR Thermometry during RF Hyperthermia of Soft Tissue Sarcomas
M. Göger-Neff, S. Karkavitsas, B. Zilles, O. Dietrich, C. Boehm (Munich/DE)
 D. Karampinos (Munich/DE, Lausanne/CH), L. H. Lindner, M. Wu (Munich/DE)
- 09:15–09:30 **OP-020** – The need and utility of an independent multichannel measuring system in Hyperthermia
F. Rogier, A. Ameziane, S. Curto, P. V. Granton (Rotterdam/NL)
- 09:30–09:45 **OP-021** – Hyperthermia Quality Assurance Program of the SAKK 57/24 TNT-HYPE multicenter phase II soft tissue sarcoma study
D. Marder (Aarau/CH), M. Fürstner (Bern/CH)
 L. Milan, M. Casiraghi, (Bellinzona/CH), O. Timm, A. Ademaj, R. A. Hälgl
 E. Puric (Aarau/CH), A. Kollar, G. Wicki (Bern/CH), O. Riesterer (Aarau/CH)
 E. Stutz (Bern/CH)
- 09:45–10:00 **OP-022** – Two-layer Hybrid Optimization for Hyperthermia Treatment Planning: Surrogate Optimization Combined with Pattern Search
M. Mrazkova, J. Redr, T. Drizdal (Kladno/CZ)
- 10:00–10:15 **OP-023** – Compensation of Flow-Induced Thermal Washout in Large-Volume MR-HIFU Hyperthermia Using a Perfusion-Adaptive Control Algorithm in a Dynamic Flow Phantom
 M. Ayary (Cologne/DE)

- 10:15–10:30 **OP-024** – Accurate Characterization of ALBA ON 4000D superficial hyperthermia applicators using robotized high-resolution E-field scans
R. Zweije, P. Kok, J. Crezee (Amsterdam/NL)
- 11:00–11:30 **Keynote 2**
Room Lecture hall 1
Chair E. Stutz (Bern/CH)
- 11:00–11:30 **KL-002** – Hyperthermia in randomized clinical trials
O. Riesterer (Aarau/CH)
- 11:30–13:00 **Clinical implementation multimodal therapies**
Room Lecture hall 1
Chair K. Brück (Amsterdam/NL), R. Issels (Munich/DE)
- 11:30–11:45 **OP-025** – Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic melanoma oligoprogression treated with radiotherapy and radiotherapy with hyperthermia
A. Borkowska, P. Chmiel, H. Koseła-Paterczyk, P. Ł. Rutkowski
M. J. Spalek (Warszawa/PL)
- 11:45–12:00 **OP-026** – Both skin and invasive temperatures should be monitored in locoregional recurrent breast cancer patients treated with postoperative re-irradiation and superficial hyperthermia exceeding 1 cm target depth
J. Crezee, P. Tello Valverde, W. Kolff, D. van den Bongard, B. Slotman (Amsterdam/NL), A. Bakker (Utrecht/NL), P. Kok (Amsterdam/NL)
- 12:00–12:15 **OP-027** – Transient IL-15 induction following whole-body hyperthermia in patients with solid tumors
T. Logghe (Antwerp, Leuven/BE), L. Brancato (Leuven/BE), T. Vandamme, V. Saldien, R. Dankerlui, M. Peeters, T. Chapelle, D. Ysebaert (Antwerp/BE)
L. Van den Bossche, J. Van den Bossche (Leuven/BE), J. Bogers (Leuven, Antwerp/BE)
- 12:15–12:30 **OP-028** – Absorbed SARhotspot as a predictor of treatment-limiting complaints in deep hyperthermia
A. Rink, H. Westerveld, M. Franckena, P. V. Granton, I. Popescu, A. Ameziane, A. Cruz Perdomo, R. A. Nout, S. Curto (Rotterdam/NL)

- 12:30–12:45 **OP-029** – Clinical utility of quality assurance approaches for phased-array hyperthermia applicators
M. Paulides (Eindhoven, Rotterdam/NL), D. Phal, K. Sümser (Eindhoven/NL)
P. V. Granton, S. Curto (Rotterdam/NL)
- 12:45–13:00 **OP-030** – Superficial Hyperthermia and Hypofractionated Palliative Radiotherapy in locally advanced, metastatic or recurrent Head-and-Neck Cancer
M. Huiskes, J. Crezee, P. Kok, A. Al-Mamgani (Amsterdam/NL)
- 13:45–14:15 **Keynote 3**
Room Lecture hall 1
Chair U. S. Gaipl (Erlangen/DE)
- 13:45–14:15 **KL-003** – Thermosensitive liposomes: how heat contributes to targeted delivery of cytotoxic drugs: challenges in the translation from lab into clinic
L. H. Lindner (Munich/DE)
- 14:15–15:30 **Innovative multimodal delivery techniques**
Room Lecture hall 1
Chair N. Shetake (Mumbai/IN), M. Paulides (Eindhoven/NL)
- 14:15–14:45 **OP-034** – Magnetic Hyperthermia 2.0: Improving Therapy Response through the Lens of Immunogenic Cell Death
N. Shetake, A. Kumar, B. Pandey (Mumbai/IN)
- 14:45–15:00 **OP-032** – Beyond Heat: Multimodal Nanotechnology Strategies to Redefine Magnetic Hyperthermia
T. Kaur, D. Sharma (Mohali, Punjab/IN)
- 15:00–15:15 **OP-031** – Thermosensitive Liposomal Irinotecan Combined with Regional Hyperthermia in Pancreatic Cancer: A Preclinical Proof-of-Concept Study
L. M. Berclaz, M. J. Egenhöfer, V. Nikitchenko (Munich/DE),
M. Hossann (Munich, Planegg/Martinsried/DE), M. Göger-Neff, R. L. Zuber
A. Burkhard-Meier, D. Di Gioia, L. Jubran-Rudolf, K. Steiger, C. Mogler (Munich/DE)
B. Kahlert, U. S. Gaipl (Erlangen/DE), M. Zuk, M. Wierzbicka
J. Burhenne (Heidelberg/DE), S. Kobold, K. Lauber, M. von Bergwelt-Baildon
L. H. Lindner (Munich/DE)

- 15:15–15:30 **OP-033** – MR-HIFU mediated Hyperthermia for Targeted Chemotherapy: Dose and Duration Optimization of doxorubicin containing DPPG₂-TSLs
C. J. Haats, M. Ayary, L. M. Hamacher, B. L. Mink, H. Grüll (Cologne/DE)
- 15:30–16:00 **ESHO Award 2026**
Room Lecture hall 1
- 16:00–16:30 **ESHO General Assembly**
Room Lecture hall 2
- 16:30–18:00 **Technical, clinical, innovative, educational, legal and economic aspects**
Room Lecture hall 1
Chair M. Göger-Neff (Munich/DE), C. Bert (Erlangen/DE)
- 16:30–16:45 **OP-035** – Hazard Assessment of Breast Implants During Regional Hyperthermia (RHT)
S. Abdel-Rahman, M. Göger-Neff, B. Zilles, N. Amleh, L. H. Lindner, R. Issels D. Di Gioia (Munich/DE)
- 16:45–17:00 **OP-036** – MR-guided Hyperthermia for Breast Cancer: Effects of Coil Integration on Heating Performance
A. de Boer (Rotterdam/NL), N. Bijl (Eindhoven/NL), I. Androulakis, M. Zanoli (Rotterdam/NL), K. Sümser, M. Paulides (Eindhoven/NL), S. Curto (Rotterdam/NL)
- 17:00–17:15 **OP-037** – The Landscape of Hyperthermia in European Radiation Oncology: Practice Patterns and Barriers to Implementation – Results from the ESTRO Hyperthermia Focus Group Survey of 48 Centers
E. Stutz, N. Bachmann (Bern/CH), A. Ademaj (Aarau/CH), P. Ghadjar (Berlin/DE) J. Contreras (Malaga/ES), S. Ramella (Rome/IT)
L. Ferrera (Las Palmas de Gran Canaria/ES), A. Borkowska (Warszawa/PL)
D. De Vries - Huizing (Amsterdam/NL), K. Olsson Hermanova (Prague/CZ)
A. Rink (Rotterdam/NL), I. Vasiliadou (London/GB)
H. Dobsicek Trefna, (Gothenburg/SE), U. S. Gaipf (Erlangen/DE), O. Riesterer (Aarau/CH)
J. Crezee (Amsterdam/NL), S. Curto (Rotterdam/NL)
- 17:15–17:30 **OP-038** – Therapeutic Integration of Hyperthermia in Modern Oncology: Establishing the First National Practice Standards and Regulatory Roadmap in Romania (The SRHO Whitepaper)
C. Gologan (Clinceni/RO), F. Giammaria (Pesaro/IT, Clinceni/RO)
H. Şahinbaş (Clinceni/RO, Oldenburg/DE), V. Iatan
M. Codrut (Clinceni, Bucharest/RO), V. Virgil (Clinceni/RO)

- 17:30–17:45 **OP-039** – The European School of Thermotherapy: advancing clinical education in hyperthermia combined with radiotherapy
A. Rink (Rotterdam/NL), D. De Vries - Huizing (Amsterdam/NL)
A. de Boer (Rotterdam/NL), R. de Kroon - Oldenhof (Amsterdam/NL), I. Lieben
M. Franckena, H. Westerveld (Rotterdam/NL), J. Crezee (Amsterdam/NL)
S. Curto (Rotterdam/NL)
- 17:45–18:00 **OP-040** – Role of CRS-HIPEC in Carcinoma Ovary: Where Do We Stand Today? Experience from a Tertiary Referral Oncology Centre in India
M. Ray (New Delhi/IN)
- 18:00–18:30 **Introducing ESTRO HT FG**
Room Lecture hall 1
- 18:00–18:30 Introducing ESTRO HT FG
S. Curto (Rotterdam/NL)
- 19:00–22:00 **Social evening** (see page 20)

08:30–09:00	Introducing ESHO Capacitive HT Working Group
Room	Lecture hall 1
08:30–09:00	Introducing ESHO Capacitive HT Working Group P. Ghadjar (Berlin/DE)
09:00–09:30	Keynote 4
Room	Lecture hall 1
Chair	J. Crezee (Amsterdam/NL)
09:00–09:30	KL-004 – A century of hyperthermic oncology in Europe – a family and personal experience J. Overgaard (Aarhus/DK)
09:30–10:15	Challenges of acceptance of HT
Room	Lecture hall 1
Chair	S. Corradini (Erlangen/DE)
09:30–09:40	OP-041 – The Future of Hyperthermia Is Not Heat! M. Paulides (Eindhoven/NL)
09:40–09:50	OP-042 – From Evidence to Acceptance: Lessons Learned from Multicentre Clinical Trials S. Spampinato (Rotterdam/NL)
09:50–10:15	OP-043 – General Discussion M. Paulides (Eindhoven/NL), S. Spampinato (Rotterdam/NL), U. S. Gaipl (Erlangen/DE) J. Crezee, K. Brück (Amsterdam/NL)
10:45–12:00	Poster Session
Room	Seminar room 1 & 2
12:00–13:30	Biology, translation and model systems
Room	Lecture hall 1
Chair	A. L. Oei (Amsterdam/NL), B. Frey (Erlangen/DE)
12:00–12:15	OP-044 – Profiles of therapeutically relevant thermophysical and oxygenation-related traits of tissue layers exposed to combined thermo-radiotherapy of breast cancers <u>A. R. Thomsen</u> (Freiburg i. Br./DE), H. Piazena (Berlin/DE), A.-M. Luchtenborg P. Vaupel (Freiburg i. Br./DE)

- 12:15–12:30 **OP-045** – Cryo-thermal therapy reprograms myeloid cells into CCL5+ mature phenotype to increase T-cell infiltration and potentiates anti-PD-1 therapy
Y. Hao, K. Wang, X. Liu, P. Liu (Shanghai/CN)
- 12:30–12:45 **OP-046** – Transient necroptosis induction combined with chemo- or thermoradiotherapy as a synergistic immune inducer for low toxicity, sustained cervical cancer therapy
S.-F. Fobian, A. L. Oei, E. Eldering, J. Tromp (Amsterdam/NL)
- 12:45–13:00 **OP-047** – Effect of Hyperthermia and Radiotherapy Combination on DNA Damage Repair and Immune Phenotype of Breast Cancer Cells
A. Sengedorj (Erlangen/DE), F. Lobo Cerna, E. Scutigliani
R. Hoebe (Amsterdam/DE), B. Frey, M. Rückert, R. Fietkau, S. Corradini
O. J. Ott (Erlangen/DE), P. Krawczyk (Amsterdam/DE), U. S. Gaipl (Erlangen/DE)
- 13:00–13:15 **OP-048** – Mitochondria-targeted precision hyperthermia therapy in triple negative breast cancer cells by bioengineered gold nanoparticles
B. Patel, N. Shetake, M. Lopus, B. Pandey (Mumbai/IN)
- 13:15–13:30 **OP-049** – Immunomonitoring of patients with anal carcinoma treated with deep regional hyperthermia in combination with standard radiochemotherapy – first results of the HYCAN trial
A.-J. Donaubauer, L. Mogge, O. J. Ott (Erlangen/DE), C. Gani (Tübingen/DE),
G. Klautke (Chemnitz/DE), O. Riesterer (Aarau/CH), E. Stutz (Bern/CH)
R. Fietkau, S. Corradini, B. Frey, U. S. Gaipl (Erlangen/DE)
- 13:30–14:30 **Industrial Symposium**
Room Lecture hall 1
- 13:30–13:45 Focused Thermotherapy. Radiotherapy Principles. Thermotherapy: the radiotherapy way
Sensius BV
E. Oberacker (Berlin/DE), T. Huitema (London/GB)

- 14:30–15:00 **Keynote 5**
 Room Lecture hall 1
 Chair S. Corradini (Erlangen/DE)
- 14:30–15:00 **KL-005** – Keeping Hyperthermia Relevant: Evidence, Visibility, and Integration in Modern Oncology
 J. Verhoeff (Amsterdam/NL)
- 15:00–16:30 **Clinical trials**
 Room Lecture hall 1
 Chair T. Lushchaeva (Magdeburg/DE), O. J. Ott (Erlangen/DE)
- 15:00–15:15 **OP-050** – Phase II feasibility study of MR-guided hyperthermia combined with chemoradiotherapy for locally recurrent rectal cancer: Integration of ctDNA methylation as a biomarker of hypoxia-driven resistance
C. Schuurhuizen, J. Hernandez Tamames, P. V. Granton, A. Rink, H. Westerveld S. Curto (Rotterdam/NL)
- 15:15–15:30 **OP-051** – Sequencing of Hyperthermia and Re-irradiation in Locoregional Recurrent Breast Cancer – A Pilot Randomized Trial (SEQUENCE)
 A. Ademaj, O. Riesterer, S. on behalf of the Swiss Hyperthermia Network (Aarau/CH), F. G. on behalf of ESTRO Hyperthermia FG (Rotterdam/NL)
- 15:30–15:45 **OP-052** – Proposed new study: ThermoRad-BC study, a randomised phase 2 study of the addition of Thermotherapy (superficial hyperthermia by wIRA) with palliative Radiotherapy plus systemic treatment versus systemic treatment in patients with local recurrent Breast Cancers (LRBC),
A. Kong, T. McKenzie, M. Khan, G. Wojewodka, J. Kang (London/GB)
- 15:45–16:00 **OP-053** – Feasibility of Total Neoadjuvant Treatment with Hyperthermia in Patients with Sarculator high-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE). A Multicenter, Single Arm, Open Label, Phase II Trial of the Swiss Cancer Institute (SAKK 57/24)
E. Stutz (Bern/CH), L. H. Lindner (Munich/DE), D. Dietrich (Bern/CH), O. Riesterer (Aarau/CH), T. Zilli (Bellinzona/CH), A. Digkha (Lausanne/CH) F. Krasniqi (Basel/CH), L. Bankel (Zurich/CH), K.-L. Koster (St. Gallen/CH) R. Zachariah (Winterthur/CH), A. Kollar (Bern/CH)

- 16:00–16:15 **OP-054** – Ongoing Report of a Pilot Study of Chemoimmunotherapy Combined with Hyperthermia and Spatially-fractionated Radiotherapy in Biliary Tract and Hepatocellular Cancers
J. Molitoris, D. Rodrigues, C. Eggleston, P. Maglo, S. Mossahebi
A. Ciner (Baltimore, MD/US)
- 16:15–16:30 **OP-055** – Mild Superficial wIRA-Hyperthermia Combined with Hypofractionated Radiotherapy in Locally Recurrent Breast Cancer – First Results of the HISTOTHERM study
A.-M. Lüchtenborg, J. Sahlmann, P. Vaupel, A.-L. Grosu, A. R. Thomsen (Freiburg i. Br./DE)
- 17:00–17:45 **Round Table: “Where we go”**
Room Lecture hall 1
- Clinical Hyperthermia in North America: Current Status, Challenges, and Opportunities
D. Rodrigues (Baltimore, MD/US)
- 17:45–18:00 **Farewell**
Room Lecture hall 1

conventus
CONGRESSMANAGEMENT


**WE BRING EVERYONE
TOGETHER**

Smart
solutions,
built to
last.

conventus.de

Your vision. Our expertise.

FLOOR PLAN/EXHIBITION



Booth

Name of company

- | | |
|---|-----------------------------------|
| 1 | Dr. Sennewald Medizintechnik GmbH |
| 2 | Sensius BV |
| 3 | ALBA - MEDLOGIX EU |
| 4 | heckel medizintechnik GmbH |
| 5 | Andromedic SRL |

State at printing

We thank the following companies for their support:

Gold sponsor

Dr. Sennewald Medizintechnik GmbH



Silver sponsor

ALBA - MEDLOGIX EU



Bronze sponsor

Sensius BV



Further sponsors

heckel medizintechnik GmbH

Andromedic SRL

MDPI

Endorsed by

DEGRO Academy



ESTRO



State at printing

SOCIAL PROGRAMME

Get together

Date	Sunday, 4 October
Starting time	18:00
Location	Logenhaus Universitätsstraße 25 91054 Erlangen
Fee	Free of charge. Registration requested.




© Logenhaus Erlangen

Meet, connect & network! Join Young ESHO during the get together for a fun and informal networking activity with fellow early-career professionals from the hyperthermia community.

Social evening

Date	Monday, 5 October
Starting time	18:00
Location	Redoutensaal Theaterplatz 1 91054 Erlangen
Fee	80 EUR (registration required)

Join us for an unforgettable social evening!



© Detlef Overmann

After a day of inspiring talks and discussions, it's time to relax, connect and enjoy the evening together. Look forward to delicious food, refreshing drinks and great music from our DJ.

Come along, meet fellow attendees and colleagues, and celebrate a successful conference in a relaxed atmosphere!

We look forward to seeing you there!



EUROPEAN Society for Hyperthermic Oncology

38th Annual Meeting

2027

6–8 September

Bern | Switzerland



Sylvie/Peter Stein | stock.adobe

Save the Date!

NOTES



30+ YEARS
THE LEADER IN
HYPERTHERMIC ONCOLOGY

DR. SENNEWALD
medizintechnik gmbh



Max Mustermann Patient Import Data Import Applicator Setup Segmentation SAR Planning Evaluation

Tab #1 Tab #2 Tab #3

Frequency 1200 MHz

Numerical Shift Geometrical Shift

Phase (°) Amplitude (%)

Top A 0 100

B 0 100

C 0 100

Bottom A 100

B 100

C 100

Patient Left A 100

Patient Right A 100

B 0 100

C 0 100

Focus Shift

Patient Left 33 mm

Anterior -11 mm

Approve Plan

Contour	SAR90 [W/kg]	SAR50 [W/kg]	SAR Mean [W/kg]	SAR Min [W/kg]	SAR Max [W/kg]
Body	0.0	4.4	19.7	0.0	307.6
PTV	90.4	133.8	135.0	16.1	213.7
Lungs	0.0	0.0	0.6	0.0	323.3
Ventr_L_Sept	7.4	16.9	17.4	3.8	29.0
Femur_Head	1.5	11.0	11.7	1.2	26.5
Diaphragm	0.0	21.3	20.7	0.1	44.3
Bone_Bum_R	17.6	25.7	28.0	13.7	70.2
Bone_Bum_L	14.7	22.1	24.8	12.7	63.1
Ventr_L_Lat	1.5	3.7	6.5	1.0	33.3
Blood_Small	44.9	91.2	95.7	0.0	211.8
Blood_Large	16.7	21.7	23.1	0.0	42.8
Heart	4.1	18.0	19.0	0.0	100.7

Sagittal
Ref: 25512
WV: 4050/010210

HYPERPLAN

OUR CERTIFIED PLANNING SOFTWARE

CE

Save Close Print Animation 2025 Completed Kim Human, 05/17/1978, DICOM ID 8901234567

SENNEWALD.DE

